RxDoctor Payments Data

Kathryn Huhmann, NP

Nurse Practitioner · Omaha, NENPI 1760978464

Payments from drug & device makers

$3,286in general payments, 2019–2025

Across 105 payments — averaging $31.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$613
  • Sumitomo Pharma America, Inc.$536
  • Astellas Pharma US Inc$519
  • Boston Scientific$342
  • Myovant Sciences Inc.$264
  • Mayne Pharma Commercial LLC$190
  • plus $822 from 14 others

What the payments were for

  • Food & beverage$3,10795%
  • Education$1795%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,286 in reported general payments places this provider in the 85th percentile of 924 nurse practitioner providers in Nebraska.

See all nurse practitioner providers in Nebraska

Medicare billing

Part B allowed, 2024
$45,518
Medicare patients
224
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron268$180,513
MyrbetriqMirabegron219$149,229
Methenamine Hippurate207$13,802
Estradiol170$13,523
Solifenacin Succinate96$5,693
ImvexxyEstradiol11$2,856
Clobetasol Propionate40$1,191
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst56$715
Oxybutynin Chloride ErOxybutynin Chloride36$471
Cefdinir15$171
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$164
Metronidazole20$142
Ciprofloxacin Hcl21$140
Cephalexin27$123
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim25$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$536$180,513268 claims
Astellas Pharma US IncMyrbetriq$519$149,229219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 924 nurse practitioner providers in Nebraska.

Other nurse practitioner in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →